GSR and Charlie Lee Lead $100M Investment into MEI, Reveal Institutional LTC Treasury Strategy

Key Points

1. GSR and Charlie Lee are leading a $100M private investment in public equity (PIPE) into Nasdaq-listed MEI Pharma, with participation from the Litecoin Foundation and other firms.

2. The investment is described as a significant step toward institutionalizing Litecoin as a treasury asset, reflecting growing institutional confidence in LTC.

3. Charlie Lee will join MEI's board of directors, and GSR will serve as an execution partner, working closely with MEI and the Litecoin Foundation.

4. MEI Pharma reported $23.7M in cash and no debt as of December 2024, while GSR has been active in supporting blockchain ecosystems, including Polygon-based Katana.

5. Litecoin's price has shown recent gains, trading at $106, up 6.9% in a day and 46% over the past year, though still down 74.1% from its all-time high in May 2021.